{
  "items": "17",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "CMS sets final payment rate of $854 for Cardio Diagnostics tests",
      "url": "https://in.investing.com/news/company-news/cms-sets-final-payment-rate-of-854-for-cardio-diagnostics-tests-93CH-5135764",
      "time_published": "20251205T040950",
      "authors": [
        "Investing.com"
      ],
      "summary": "The Centers for Medicare and Medicaid Services (CMS) has finalized a gapfill payment rate of $854 for Cardio Diagnostics Holdings, Inc.'s Epi+Gen CHD and PrecisionCHD tests, a significant increase from preliminary rates. This new rate, effective January 1, 2026, is expected to expand access to these cardiovascular diagnostic tests for Medicare beneficiaries. Despite the company's stock falling nearly 90% year-to-date, this development, along with recent partnerships, reflects efforts to strengthen its market position in addressing coronary heart disease.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com India",
      "category_within_source": "General",
      "source_domain": "Investing.com India",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948039"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.748772"
        }
      ],
      "overall_sentiment_score": 0.482531,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.460601",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Receives Final Gapfill Payment Rates for AI-Driven Cardiovascular Tests from the Centers for Medicare and Medicaid Services (CMS)",
      "url": "https://www.businesswire.com/news/home/20251203479342/en/Cardio-Diagnostics-Receives-Final-Gapfill-Payment-Rates-for-AI-Driven-Cardiovascular-Tests-from-the-Centers-for-Medicare-and-Medicaid-Services-CMS",
      "time_published": "20251204T035411",
      "authors": [
        "NULL"
      ],
      "summary": "Cardio Diagnostics Holdings, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for its Epi+Gen CHD\u2122 and PrecisionCHD\u2122 AI-powered cardiovascular tests. This rate is an increase from preliminary rates and will be effective for claims on or after January 1, 2026. This development significantly expands access to these advanced tests for Medicare beneficiaries, aiming to combat cardiovascular disease, the leading cause of death in the US.",
      "banner_image": "https://mms.businesswire.com/media/20251203479342/en/2659437/4/CARDIO_LOGO.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929802"
        },
        {
          "topic": "technology",
          "relevance_score": "0.817698"
        },
        {
          "topic": "finance",
          "relevance_score": "0.638865"
        }
      ],
      "overall_sentiment_score": 0.251942,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.961619",
          "ticker_sentiment_score": "0.471181",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "CMS",
          "relevance_score": "0.632990",
          "ticker_sentiment_score": "0.246847",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GEHC",
          "relevance_score": "0.553810",
          "ticker_sentiment_score": "0.117859",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holdings, Inc. to Present Data Demonstrating PrecisionCHD\u2019s Ability to Detect INOCA and MINOCA at the American Heart Association Scientific Sessions",
      "url": "https://www.businesswire.com/news/home/20251105196979/en/Cardio-Diagnostics-Holdings-Inc.-to-Present-Data-Demonstrating-PrecisionCHDs-Ability-to-Detect-INOCA-and-MINOCA-at-the-American-Heart-Association-Scientific-Sessions",
      "time_published": "20251108T035411",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings, Inc. will present new data at the American Heart Association Scientific Sessions, highlighting their PrecisionCHD test's capability to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA). These conditions are often underdiagnosed by standard methods but are significant causes of mortality. The study, conducted in collaboration with the University of Iowa, demonstrated high accuracy and personalized insights from PrecisionCHD's DNA methylation markers, paving the way for more precise and accessible cardiovascular medicine, especially for at-risk populations.",
      "banner_image": "https://mms.businesswire.com/media/20251105196979/en/2633102/4/CARDIO_LOGO.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "technology",
          "relevance_score": "0.811756"
        }
      ],
      "overall_sentiment_score": 0.044388,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.324828",
          "ticker_sentiment_score": "0.043844",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holdings, Inc. and YMCA of East Tennessee Partner to Bring Heart Health Education and Advanced Testing to East Tennessee Community",
      "url": "https://www.businesswire.com/news/home/20251028273603/en/Cardio-Diagnostics-Holdings-Inc.-and-YMCA-of-East-Tennessee-Partner-to-Bring-Heart-Health-Education-and-Advanced-Testing-to-East-Tennessee-Community",
      "time_published": "20251108T035411",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings, Inc. is partnering with the YMCA of East Tennessee to provide heart health education and advanced AI-powered cardiovascular testing to its members and the wider East Tennessee community. The program includes \"Wisdom Wednesdays\" educational sessions and discounted access to Cardio Diagnostics' Epi+Gen CHD\u2122 and PrecisionCHD\u2122 clinical tests, addressing the high rates of heart disease in Tennessee. This collaboration aims to empower individuals with early detection tools and actionable insights to proactively manage and prevent cardiovascular disease.",
      "banner_image": "https://mms.businesswire.com/media/20251028273603/en/2623027/4/logo_%281%29.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.994355"
        },
        {
          "topic": "technology",
          "relevance_score": "0.708848"
        },
        {
          "topic": "finance",
          "relevance_score": "0.625630"
        }
      ],
      "overall_sentiment_score": 0.460064,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.475291",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holdings, Inc. Expands Provider Network, Adding 15 New Provider Organizations From Across the United States",
      "url": "https://www.businesswire.com/news/home/20251021905340/en/Cardio-Diagnostics-Holdings-Inc.-Expands-Provider-Network-Adding-15-New-Provider-Organizations-From-Across-the-United-States",
      "time_published": "20251108T035411",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has expanded its provider network by partnering with 15 new organizations across the U.S. This expansion highlights the growing adoption of its AI-driven precision cardiovascular medicine tests, Epi+Gen CHD\u2122 and PrecisionCHD\u2122, across various care models. These partnerships aim to make advanced cardiovascular care more accessible, enhancing patient outcomes through personalized treatment plans.",
      "banner_image": "https://mms.businesswire.com/media/20251021905340/en/2615706/4/CARDIO_LOGO.jpg",
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908906"
        },
        {
          "topic": "technology",
          "relevance_score": "0.737309"
        }
      ],
      "overall_sentiment_score": 0.461939,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.453920",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology",
      "url": "https://www.businesswire.com/news/home/20250610505138/en/Cardio-Diagnostics-Secures-Japanese-Patent-for-AI-Driven-Cardiovascular-Disease-Detection-Technology",
      "time_published": "20251102T112511",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings Inc. announced it has secured a Japanese patent for its AI-driven technology used in detecting predisposition to cardiovascular disease. This patent expands the company's global intellectual property portfolio, strengthening its presence in international markets. The technology leverages epigenetic and genetic biomarkers with machine learning for early detection and prevention of heart disease.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "technology",
          "relevance_score": "0.821920"
        }
      ],
      "overall_sentiment_score": 0.948525,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.912181",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics (NASDAQ: CDIO) to host Wisdom Wednesdays with YMCA starting Nov 2025",
      "url": "https://www.stocktitan.net/news/CDIO/cardio-diagnostics-holdings-inc-and-ymca-of-east-tennessee-partner-9r3d0585gdiy.html",
      "time_published": "20251028T083500",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings, Inc. is partnering with the YMCA of East Tennessee to launch a program featuring \"Wisdom Wednesdays\" educational sessions and discounted AI-powered cardiovascular testing for YMCA members. This initiative aims to combat heart disease, a leading cause of death in Tennessee, by providing education and access to early detection tools like Epi+Gen CHD and PrecisionCHD tests. The program is set to begin in November 2025, with a Heart Health Fair planned for February 2026.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.405914,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.420464",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics shareholders approve director slate and key proposals at annual meeting - Investing.com Nigeria",
      "url": "https://ng.investing.com/news/sec-filings/cardio-diagnostics-shareholders-approve-director-slate-and-key-proposals-at-annual-meeting-93CH-2148176",
      "time_published": "20251016T002638",
      "authors": [],
      "summary": "This article reports that an application error occurred while attempting to load content regarding Cardio Diagnostics shareholders' approval of a director slate and key proposals at their annual meeting. As a result, the specific details of the meeting outcomes are not available.",
      "banner_image": null,
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.918839"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.631108"
        },
        {
          "topic": "finance",
          "relevance_score": "0.449091"
        }
      ],
      "overall_sentiment_score": 0.040948,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.319398",
          "ticker_sentiment_score": "0.040528",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holds Annual Stockholders Meeting - TipRanks",
      "url": "https://www.tipranks.com/news/company-announcements/cardio-diagnostics-holds-annual-stockholders-meeting",
      "time_published": "20251015T212734",
      "authors": [
        "TipRanks Auto-Generated Newsdesk"
      ],
      "summary": "Cardio Diagnostics Holdings held its annual stockholders meeting on October 15, 2025, where shareholders elected seven directors and approved additional share issuance. They also ratified Prager Metis CPA\u2019s LLC as their independent accounting firm for the fiscal year ending December 31, 2025. These decisions are set to influence the company\u2019s strategic and financial operations as it continues its work in cardiovascular health assessment.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2051377127-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.948257"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.746107"
        },
        {
          "topic": "finance",
          "relevance_score": "0.446934"
        }
      ],
      "overall_sentiment_score": 0.024506,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.343117",
          "ticker_sentiment_score": "0.000400",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics shareholders approve director slate and key proposals at annual meeting By Investing.com - Investing.com South Africa",
      "url": "https://m.za.investing.com/news/sec-filings/cardio-diagnostics-shareholders-approve-director-slate-and-key-proposals-at-annual-meeting-93CH-3922951?ampMode=1",
      "time_published": "20251015T212245",
      "authors": [
        "Investing.com"
      ],
      "summary": "Cardio Diagnostics Holdings, Inc. shareholders approved the election of seven directors and two key proposals at their annual meeting. The proposals included authorizing the potential issuance of common stock and ratifying the appointment of Prager Metis CPA\u2019s LLC as the independent registered public accounting firm for 2025. This follows recent news of preliminary gapfill payment rates from CMS for two of the company's cardiovascular tests.",
      "banner_image": "https://i-invdn-com.investing.com/news/international_newspapers_108x81.jpg",
      "source": "Investing.com South Africa",
      "category_within_source": "General",
      "source_domain": "Investing.com South Africa",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938970"
        },
        {
          "topic": "finance",
          "relevance_score": "0.724990"
        }
      ],
      "overall_sentiment_score": 0.010211,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.320688",
          "ticker_sentiment_score": "0.000251",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics shareholders approve director slate and key proposals at annual meeting - Investing.com",
      "url": "https://www.investing.com/news/sec-filings/cardio-diagnostics-shareholders-approve-director-slate-and-key-proposals-at-annual-meeting-93CH-4290932",
      "time_published": "20251015T210118",
      "authors": [],
      "summary": "This article indicates that there was an application error while attempting to load content regarding Cardio Diagnostics shareholder approvals. Therefore, no specific details about the annual meeting or proposals are available within the provided text. The mention of a \"FLASH SALE: 50% off InvestingPro\" suggests the article might have been behind a paywall or part of a promotional campaign.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.503538"
        }
      ],
      "overall_sentiment_score": 0.032701,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.347878",
          "ticker_sentiment_score": "0.038974",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Can Cardio Diagnostics Holdings Inc. stock continue upward trend - Market Volume Report & Low Drawdown Momentum Trade Ideas - newser.com",
      "url": "https://www.newser.com/story/376038/Can-Cardio-Diagnostics-Holdings-Inc.-stock-continue-upward-trend",
      "time_published": "20251015T165543",
      "authors": [],
      "summary": "The provided content indicates a \"403 Forbidden\" error, suggesting that the article itself is not accessible. Therefore, it is impossible to determine whether Cardio Diagnostics Holdings Inc. stock will continue its upward trend based on this information.",
      "banner_image": null,
      "source": "newser.com",
      "category_within_source": "General",
      "source_domain": "newser.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.931907"
        }
      ],
      "overall_sentiment_score": 0.011528,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "0.328514",
          "ticker_sentiment_score": "0.035752",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics secures Japan patent for heart disease biomarkers",
      "url": "https://www.investing.com/news/company-news/cardio-diagnostics-secures-japan-patent-for-heart-disease-biomarkers-93CH-4088820",
      "time_published": "20251006T084600",
      "authors": [
        "Investing.com"
      ],
      "summary": "Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO) has been granted a patent by the Japan Patent Office for its heart disease biomarkers, expanding its international intellectual property portfolio. This patent, licensed from the University of Iowa Research Foundation, covers compositions and methods for detecting predisposition to cardiovascular disease using AI-powered genetic and epigenetic diagnostics. The company also recently announced a 1-for-30 reverse stock split to comply with Nasdaq's minimum bid price requirement.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943110"
        },
        {
          "topic": "technology",
          "relevance_score": "0.838387"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.737196"
        }
      ],
      "overall_sentiment_score": 0.443157,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.448752",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics secures Japanese patent for AI-driven cardiovascular disease detection technology",
      "url": "https://www.biospectrumasia.com/news/50/26177/cardio-diagnostics-secures-japanese-patent-for-ai-driven-cardiovascular-disease-detection-technology.html",
      "time_published": "20250610T050912",
      "authors": [
        "NULL"
      ],
      "summary": "Cardio Diagnostics Holdings Inc. has secured a Japanese patent for its AI-powered cardiovascular disease detection technology, marking a significant step in globalizing its precision medicine platform. This patent strengthens the company's intellectual property portfolio, which already includes patents in the US, Europe, Australia, India, and China. The technology uses epigenetic and genetic biomarkers combined with machine learning to detect cardiovascular disease risk, highlighting its global applicability in improving early detection and prevention.",
      "banner_image": "https://www.biospectrumasia.com/uploads/articles/card-26177.jpg",
      "source": "BioSpectrum Asia",
      "category_within_source": "General",
      "source_domain": "BioSpectrum Asia",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932383"
        },
        {
          "topic": "technology",
          "relevance_score": "0.839052"
        }
      ],
      "overall_sentiment_score": 0.48248,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.461166",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split",
      "url": "https://www.businesswire.com/news/home/20250508912802/en/Cardio-Diagnostics-Holdings-Inc.-Announces-1-for-30-Reverse-Stock-Split",
      "time_published": "20250502T000000",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings, Inc. announced a 1-for-30 reverse stock split of its common stock, effective May 13, 2025, to regain compliance with Nasdaq's minimum bid price requirement. This action, approved by stockholders and the Board, will reduce outstanding shares from approximately 52 million to 1.7 million and adjust related securities. The company's stock will trade on a post-split basis under the existing ticker CDIO with a new CUSIP number.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.914190"
        },
        {
          "topic": "finance",
          "relevance_score": "0.815512"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.732754"
        }
      ],
      "overall_sentiment_score": 0.112745,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.146392",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests",
      "url": "https://www.biospace.com/press-releases/cardio-diagnostics-holdings-inc-receives-preliminary-medicare-pricing-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests",
      "time_published": "20241002T050913",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings, Inc. has received preliminary pricing determinations from CMS for its AI-powered cardiovascular tests, PrecisionCHD and Epi+Gen CHD. This critical milestone moves the company closer to securing Medicare reimbursement, which will enhance accessibility to its innovative blood tests for Medicare patients. The decision empowers Medicare contractors to determine pricing based on actual cost data, effective January 1, 2025, significantly improving the diagnosis, management, and monitoring of coronary heart disease.",
      "banner_image": "https://mms.businesswire.com/media/20241001680555/en/2259483/22/CARDIO_LOGO.jpg",
      "source": "BioSpace",
      "category_within_source": "General",
      "source_domain": "BioSpace",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.747852"
        },
        {
          "topic": "technology",
          "relevance_score": "0.711296"
        }
      ],
      "overall_sentiment_score": 0.470661,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.455319",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Cardio Diagnostics Holdings Inc Sponsors Becker\u2019s Hospital Review 11th Annual Meeting - The CEO + CFO Roundtable",
      "url": "https://www.businesswire.com/news/home/20221108005658/en/Cardio-Diagnostics-Holdings-Inc-Sponsors-Beckers-Hospital-Review-11th-Annual-Meeting---The-CEO-CFO-Roundtable",
      "time_published": "20221108T162206",
      "authors": [],
      "summary": "Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) announced its sponsorship of Becker\u2019s Hospital Review 11th Annual Meeting, \"The CEO + CFO Roundtable,\" taking place from November 7-10, 2022, in Chicago. CEO Meesha Dogan, Ph.D., is sharing insights on epigenetics in heart disease at booth #120 during the conference, which gathers over 1000 healthcare leaders. Cardio Diagnostics aims to improve cardiovascular disease detection and treatment through its proprietary AI-driven Integrated Genetic-Epigenetic Engine\u2122.",
      "banner_image": null,
      "source": "Business Wire",
      "category_within_source": "General",
      "source_domain": "Business Wire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904295"
        }
      ],
      "overall_sentiment_score": 0.548269,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "CDIO",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.529065",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}